Prognostic Value of CD 44 Variant exon 6 Expression in Non-Small Cell Lung Cancer : a Meta-analysis

Shuang Zhao,Jin-Lan He,Zhi-Xin Qiu,Nian-Yong Chen,Zhuang Luo,Bo-Jiang Chen,Wei-Min Li
2014-01-01
Abstract:Lung cancer is the most common malignancy and the leading cause of cancer-related death in men and women worldwide, and non small cell lung cancer (NSCLC) accounts for about 85% of all lung cancer. Despite the improved surgical techniques and advanced therapeutic regimens, its 5-year overall survival (OS) is still only about 17% (Siegel et al., 2013). Surgery is thought the best treatment option, but only about 20-25% of tumours are suitable for potentially curative resection, and most patients have already lost the chance for curative surgery when diagnosed. Thus, there is a great need for identifying prognostic markers to help with early diagnosis and OS for NSCLC. CD44 is a multi-functional and multi-structural transmembrane glycoprotein, and it was initially characterized as a receptor for hyaluronan and lymphocytehoming receptor (Naor et al., 1997). CD44 plays an important role in prognosis of many cancers, such as bile duct cancer (Kunlabut et al., 2012), breast cancer
What problem does this paper attempt to address?